Guest
More than a decade ago, pioneering biochemist Jennifer Doudna co-invented CRISPR, the gene editing technology which earned her the Nobel Prize in chemistry. Now, the very first treatment based on CRISPR has been approved in the U.K. and the U.S., a landmark decision for the treatment of sickle cell disease and for the potential of this rapidly advancing field. Dr. Doudna joins her biographer, Walter Isaacson, to discuss what the technology could mean for the future — and the danger of its possible misuse. Originally aired on January 4, 2024 ---------------------------------------------------------------------------------------------------------------------------------------- Major support for Amanpour and Company is provided by The Anderson Family Endowment, Jim Attwood and Leslie Williams, Candace King Weir, the Leila and Mickey Straus Family Charitable Trust, Mark J. Blechner, Seton J. Melvin, Charles Rosenblum, Koo and Patricia Yuen, Barbara Hope Zuckerberg, Jeffrey Katz and Beth Rogers, Bernard and Denise Schwartz, the JPB Foundation, the Sylvia A. and Simon B. Poyta Programming Endowment to Fight Antisemitism and Josh Weston. Subscribe to the Amanpour and Company. channel here: Subscribe to our daily newsletter to find out who's on each night: For more from Amanpour and Company, including full episodes, click here: Like Amanpour and Company on Facebook: Follow Amanpour and Company on Twitter: Watch Amanpour and Company weekdays on PBS (check local listings). Amanpour and Company features wide-ranging, in-depth conversations with global thought leaders and cultural influencers on the issues and trends impacting the world each day, from politics, business and technology to arts, science and sports. Christiane Amanpour leads the conversation on global and domestic news from London with contributions by prominent journalists Walter Isaacson, Michel Martin, Alicia Menendez and Hari Sreenivasan from the Tisch WNET Studios at Lincoln Center in New York City. #amanpourpbs
